ESR1 and breast carcinoma: The latest SERENA‐6 trial data showed that first‐line camizestrant plus a CDK4/6i significantly prolongs median PFS (16.0 vs. 9.2 months, HR = 0.44; 95% CI 0.31–0.60; p < 0.0001) compared with continued AIs‐based combination therapy in patients with newly detected ESR1‐mutant, ER(+)/HER2(−) advanced breast cancer [42].